>
Switch to:

Horizon Therapeutics Interest Expense

: $-71 Mil (TTM As of Sep. 2021)
View and export this data going back to 2011. Start your Free Trial

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Horizon Therapeutics's interest expense for the three months ended in Sep. 2021 was $ -23 Mil. Its interest expense for the trailing twelve months (TTM) ended in Sep. 2021 was $-71 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Horizon Therapeutics's Operating Income for the three months ended in Sep. 2021 was $ 332 Mil. Horizon Therapeutics's Interest Expense for the three months ended in Sep. 2021 was $ -23 Mil. Horizon Therapeutics's Interest Coverage for the quarter that ended in Sep. 2021 was 14.43. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


Horizon Therapeutics Interest Expense Historical Data

The historical data trend for Horizon Therapeutics's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Horizon Therapeutics Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Interest Expense
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -86.61 -126.52 -121.69 -87.09 -59.62

Horizon Therapeutics Quarterly Data
Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21
Interest Expense Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -12.19 -11.52 -13.46 -22.58 -22.98

Horizon Therapeutics Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Sep. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $-71 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Horizon Therapeutics  (NAS:HZNP) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Horizon Therapeutics's Interest Expense for the three months ended in Sep. 2021 was $-23 Mil. Its Operating Income for the three months ended in Sep. 2021 was $332 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Sep. 2021 was $2,558 Mil.

Horizon Therapeutics's Interest Coverage for the quarter that ended in Sep. 2021 is calculated as

Interest Coverage=-1* Operating Income (Q: Sep. 2021 )/Interest Expense (Q: Sep. 2021 )
=-1*331.543/-22.977
=14.43

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.


Horizon Therapeutics Business Description

Horizon Therapeutics logo
Industry
Healthcare » Drug Manufacturers NAICS : 325412 SIC : 2834
Traded in Other Exchanges
Address
1 Burlington Road, Connaught House, 1st Floor, Dublin, IRL, D04 C5Y6
Horizon Therapeutics PLC is a specialty and generic drug manufacturing company. The company is focused on researching, developing and commercializing medicines that address critical needs for people impacted by rare and rheumatic diseases. The company has two reportable segments: orphan and rheumatology segment and the inflammation segment. It markets medicines in the areas of orphan diseases, rheumatology and inflammation division. The majority of revenue is generated in the United States.
Executives
Sherman Jeffrey W officer: EVP and Chief Medical Officer C/O IDM PHARMA, INC. 9 PARKER, SUITE 100 IRVINE CA 92618
Camardo Daniel A. officer: EVP and President, U.S. C/O HORIZON THERAPEUTICS, PLC CONNAUGHT HOUSE, 1ST FL, 1 BURLINGTON RD DUBLIN L2 D04 C5Y6
Konstantinovsky Irina officer: EVP, Chief Human Resources Off C/O HORIZON PHARMA PLC CONNAUGHT HOUSE, 1ST FL, 1 BURLINGTON RD DUBLIN L2 4
Beeler Brian K officer: EVP, General Counsel C/O HORIZON PHARMA PLC 520 LAKE COOK ROAD, SUITE 520 DEERFIELD IL 60015
Hoelscher Paul W. officer: EVP, CFO 520 LAKE COOK ROAD, SUITE 520 C/O HORIZON PHARMA, INC. DEERFIELD IL 60062
Walbert Timothy P director, officer: Chairman, President and CEO 1033 SKOKIE BOULEVARD SUITE 355 NORTHBROOK IL 60062
Grey Michael G director C/O SGX PHARMACEUTICALS, INC. 10505 ROSELLE STREET SAN DIEGO CA 92121
Santini Gino director C/O AMAG PHARMACEUTICALS, INC. 1100 WINTER STREET WALTHAM MA 02451
Karnani Vikram officer: EVP & President, International C/O HORIZON PHARMA PLC, CONNAUGHT HOUSE 1ST FLOOR, 1 BURLINGTON RD DUBLIN L2 4
Witz Pascale director C/O REGULUS THERAPEUTICS INC. 10614 SCIENCE CENTER DRIVE SAN DIEGO CA 92121
Shannon James Samuel director 28903 NORTH AVENUE PAINE VALENCIA CA 91355
Kent Jeff officer: See remarks C/O HORIZON PHARMA PLC CONNAUGHT HOUSE, 1ST FL, 1 BURLINGTON RD DUBLIN L2 4
Moze Barry officer: EVP, Chief Admin. Officer C/O HORIZON PHARMA, INC. 520 EAST COOK ROAD, SUITE 520 DEERFIELD IL 60015
Mchugh Miles W officer: Sr VP & Princ. Acctg Officer C/O ACCRETIVE HEALTH, INC. 401 N. MICHIGAN AVE, SUITE 2700 CHICAGO IL 60611
Curtis Geoffrey M. officer: EVP, Corporate Affairs, CCO C/O HORIZON PHARMA PLC CONNAUGHT HOUSE, 1ST FL, 1 BURLINGTON RD DUBLIN L2 L2 4

Horizon Therapeutics Headlines

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)